Hims & Hers Health Stock Slides on Earnings Miss and Soft Guidance: Is $40 the Next Stop? Hims & Hers Health (HIMS) reported Q2 results after the close last night, delivering a mixed set of numbers ...

CHONGQING, CHINA - JULY 30: In this photo illustration, a person holds a smartphone displaying the logo of Hims & Hers Health Inc. (NYSE: HIMS), an American telehealth company offering personal care ...

Forbes contributors publish independent expert analyses and insights. Specializing in options trading for more than 35 years. Shares of Hims & Hers Health (HIMS) are headed for their fourth-straight ...

Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. The results reflect GLP-1 concerns. Hims & Hers' GLP-1 strategy is now on dubious grounds after Novo ...

Hims & Hers Health (HIMS) is evolving into a scaled, subscription-driven consumer health platform with strong recurring revenue potential. HIMS faces near-term headwinds from GLP-1 partnership ...

At last check, HIMS was up 0.8% to trade at $47.82. It looks like the stock could continue higher, too, as those recent losses placed the shares near a long-term trendline that has historically ...

Subscribers to Schaeffer's Weekend Trader options recommendation service received this HIMS commentary on Sunday night, along with a detailed options trade recommendation -- including complete entry ...